-
Mashup Score: 19
Original Article from The New England Journal of Medicine — Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1The Real Story of the Christmas Truce - 4 month(s) ago
The Christmas Truce has become one of the most famous and mythologised events of the First World War. But what was the real story behind the truce? Why did it happen and did British and German soldiers really play football in no-man’s land?
Source: www.iwm.org.ukCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 19
Original Article from The New England Journal of Medicine — Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1The role of TGF-β pathway in immune regulation as a potential biomarker of immunotherapy across pan-cancer. - 5 month(s) ago
e15187 Background: The transforming growth factor beta (TGF-β) signaling pathway has been reported to be involved in both tumor suppression and tumor promotion. However, the role of TGF-β pathway in immune regulation for cancer patients and its influences on immunotherapy efficacy have not been systematically investigated. Methods: Available data of whole-exome sequencing, mRNA expression, baseline characterization and prognosis information of 10,912 pancancer patients were adopted from The Cancer Genome Altas (TCGA) to explore the role of TGF-β pathway in immune regulation. Formalin-fixed, paraffin-embedded tissue samples from 6,717 Chinese patients with over 17 tumor types were assayed by next-generation sequencing with a panel with 381 cancer related genes as a validation cohort (3DMed cohort). Datasets from the public MSK cohort (N = 1,610) was used to explore the association of TGF-β pathway in patient survival. Results: The highest prevalence of single nucleotide variation (SNVs)
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 20
Positive phase III trials are not truly practice changing if they do not accurately inform on the best options for patients
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 38CTG Labs - NCBI - 5 month(s) ago
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Source: www.clinicaltrials.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 19
Original Article from The New England Journal of Medicine — Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 19
Original Article from The New England Journal of Medicine — Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 34
The emergence of positron emission tomography (PET) in prostate cancer is impacting clinical practice, but little is known about PET imaging as a tool…
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet-
What if changes seen on #ProstateCancer #PET scans didn't correlate w/tx failure "This study provides cautionary data for those who seek to use #PET imaging...to identify treatment failure in pts where conventional imaging remains stable..." @EurUrolOncol https://t.co/ST5hlaVsUZ https://t.co/XoVqwhtoC8
-
-
Mashup Score: 20
Positive phase III trials are not truly practice changing if they do not accurately inform on the best options for patients
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma @NEJM #ESMO23 #BladderCancer https://t.co/scFHqIYDsb